clinical kinase index

clinical kinase index prioritizes understudied human kinases as potential cancer drug targets by integrating The Cancer Genome Atlas genomic and clinical data to rank kinases across 17 solid tumor types.

Key Features:

• Ranking and prioritization: Ranks and prioritizes clinically relevant kinases across multiple solid tumor cancers using integrated analyses.
• Data source: Uses The Cancer Genome Atlas (TCGA) datasets covering 17 solid tumor cancer types.
• Multi-layer analysis: Incorporates differential gene expression, pathological parameters, overall survival metrics, and mutational hotspot analysis.
• Kinome scope: Evaluates the human kinome comprising 634 kinases, highlighting that 24% are understudied and that approximately 8% have been targeted by approved kinase inhibitors.
• Knowledgebase integration: Is encapsulated in the Dark Kinase Knowledgebase Application for consolidated kinase data representation.

Scientific Applications:

• Target prioritization: Prioritizes understudied kinases as candidate drug targets for cancer treatment.
• Biomarker identification: Identifies kinases with potential clinical value as biomarkers or therapeutic targets.
• Kinome exploration: Enables systematic exploration of understudied regions of the kinome across 17 solid tumor types.

Methodology:

CKI computes a composite ranking from TCGA data by combining differential gene expression, pathological parameters, overall survival metrics, and mutational hotspot analysis.